Table 3 Model inputs updated to the Greek healthcare setting used in sensitivity analysis
Model input | Values | Low values | High values | Variation |
|---|---|---|---|---|
Time horizon | 36 | 10 | 20 | Â |
Discount rate costs/outcomes | 3.50Â % | 0Â % | 7.0Â % | Â |
Baseline age | 63 | 53 | 73 | ±10 years |
Utility multiplier—BSE | 1 | 0.80 | 1.20 | ±20 % |
Utility multiplier—WSE | 1 | 0.80 | 1.20 | ±20 % |
Relative risk mortality w DME | 2.45 | 1.00 | 4.90 | ±100 % |
Odds ratio ranibizumab PRN vs aflibercept month 0–3 | 1.5949 | 0.61 | 5.37 | Standard error |
Odds ratio ranibizumab T&E vs aflibercept month 0–3 | 1.65 | 0.43 | 6.08 | Standard error |
Price of ranibizumab | €656.16a | €492.12 | €820.20 | ±25 % (of acquisition cost) |
Price of aflibercept | €613.36b | €460.02 | €766.70 | ±25 % (of acquisition cost) |
Administration cost | €66.40 | €49.80 | €83.00 | ±25 % |
Monitoring visit cost | €10.00 | €7.50 | €12.50 | ±25 % |
BCVA ≤35 year 1 | €5248.49 | €3936.37 | €6560.61 | ±25 % |
BCVA ≤35 year 2+ | €4866.49 | €3649.87 | €6083.11 | ±25 % |